GSK's Blenrep Approved in China for Relapsed/Refractory Multiple Myeloma

summarizeSummary

GSK announced that its oncology drug, Blenrep, has received approval from China's NMPA for treating relapsed or refractory multiple myeloma, expanding its global market presence.

check_boxKey Events

• China NMPA Approval

  Blenrep (belantamab mafodotin) has been approved by China's National Medical Products Administration (NMPA) for the treatment of adults with 2L+ relapsed or refractory multiple myeloma in combination with bortezomib and dexamethasone (BVd).

• Strong Clinical Data

  The approval is supported by pivotal DREAMM-7 phase III trial data, which showed a 42% reduction in the risk of death and nearly tripled median progression-free survival compared to a daratumumab-based triplet.

• Significant Market Expansion

  This approval opens a substantial new market in China, where the incidence of multiple myeloma has doubled to approximately 30,000 new cases annually.

• Differentiated Therapy

  Blenrep is highlighted as the only anti-BCMA approved in 2L+ multiple myeloma in China and the only fully outpatient anti-BCMA therapy, minimizing patient and healthcare burden.

auto_awesomeAnalysis

This approval in China for Blenrep (belantamab mafodotin) is a significant positive development for GSK, opening a substantial new market for a key oncology product. Multiple myeloma incidence in China is growing, and Blenrep offers a differentiated, outpatient anti-BCMA therapy with strong clinical data, including a 42% reduction in the risk of death and nearly tripled progression-free survival in the DREAMM-7 trial. This expands GSK's footprint in a critical therapeutic area and geographic region.